Experienced in Raynaud Phenomenon

Dr. Herbert S. Baraf

Rheumatology
2730 University Blvd W, Suite 310, 
Wheaton, MD 
Experienced in Raynaud Phenomenon
2730 University Blvd W, Suite 310, 
Wheaton, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Herbert Baraf is a Rheumatologist in Wheaton, Maryland. Dr. Baraf is rated as an Experienced provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Gout, Arthritis, Rheumatoid Arthritis (RA), and Necrotizing Vasculitis.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

2730 University Blvd W, Suite 310, Wheaton, MD 20902

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 4, Multicenter, Open-label, Efficacy and Safety Trial of Pegloticase and Methotrexate Co-administered in Patients With Uncontrolled Gout Who Have Previously Received Pegloticase Monotherapy But Did Not Maintain a Serum Uric Acid Response
A Phase 4, Multicenter, Open-label, Efficacy and Safety Trial of Pegloticase and Methotrexate Co-administered in Patients With Uncontrolled Gout Who Have Previously Received Pegloticase Monotherapy But Did Not Maintain a Serum Uric Acid Response
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug, Biological
Study Drug: Pegloticase
Study Phase: Phase 4
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
Disease Modification in Sjogrens Syndrome Measured by Ultrasound: A Pilot Study
Disease Modification in Sjogrens Syndrome Measured by Ultrasound: A Pilot Study
Enrollment Status: Unknown
Publish Date: May 11, 2021
Intervention Type: Biological, Other
Study Drug: Orencia
Study Phase: Phase 2
Elastography as Gouty Arthropathy Outcome (EGO), a Pilot Study.
Elastography as Gouty Arthropathy Outcome (EGO), a Pilot Study.
Enrollment Status: Completed
Publish Date: October 23, 2020
View 5 Less Clinical Trials

20 Total Publications

The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
Journal: Rheumatology (Oxford, England)
Published: February 08, 2023
Similar Doctors
Elite in Raynaud Phenomenon
Dr. Fredrick M. Wigley
Rheumatology
Elite in Raynaud Phenomenon
Dr. Fredrick M. Wigley
Rheumatology

Johns Hopkins University

5501 Hopkins Bayview Cir, 
Baltimore, MD 
 (32.2 miles away)
410-550-0545
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Fredrick Wigley is a Rheumatologist in Baltimore, Maryland. Dr. Wigley is rated as a Distinguished provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Raynaud Phenomenon, and Scleroma. Dr. Wigley is currently accepting new patients.

Distinguished in Raynaud Phenomenon
Dr. Laura K. Hummers
Rheumatology
Distinguished in Raynaud Phenomenon
Dr. Laura K. Hummers
Rheumatology

Johns Hopkins University

5501 Hopkins Bayview Cir, 
Baltimore, MD 
 (32.2 miles away)
410-550-0545
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Hummers is a Rheumatologist in Baltimore, Maryland. Dr. Hummers is rated as an Elite provider by MediFind in the treatment of Raynaud Phenomenon. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Eosinophilic Fasciitis, and Scleroma. Dr. Hummers is currently accepting new patients.

Distinguished in Raynaud Phenomenon
Dr. Sam W. Serafi
Rheumatology
Distinguished in Raynaud Phenomenon
Dr. Sam W. Serafi
Rheumatology

Rheumatology Associates Of Baltimore LLC

1220B East Joppa Road, Suite 324, Towson, 
Baltimore, MD 
 (36.5 miles away)
410-494-1888
Languages Spoken:
English
See accepted insurances

Sam Serafi is a Rheumatologist in Baltimore, Maryland. Dr. Serafi is rated as a Distinguished provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Fibromyalgia, Raynaud Phenomenon, Sjogren Syndrome, and Rheumatoid Arthritis (RA).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baraf's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile